分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

RNA m6A-Regulated circ-ZNF609 Suppression Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating FTO

Pujiao Yu, Jiaqi Wang, Gui-e Xu, Xuan Zhao, Xinxin Cui, Jingyi Feng, Jiangpeng Sun, Tianhui Wang, Michail Spanos, Helge Immo Lehmann, Guoping Li, Jiahong Xu, Lijun Wang, Junjie Xiao

Journal:JACC-Basic to Translational Science

IF:9.7

DOI:10.1016/j.jacbts.2022.12.005

PMID:37426524

Published:2023-03-01

research field:分子生物学免疫学遗传学眼科学

Abstract

Summary Cardiac death is a major burden for cancer survivors, yet there is currently no effective treatment for doxorubicin (DOX)-induced cardiotoxicity. Here, we report that circ-ZNF609 knockdown knockdown had cardioprotective effects against DOX-induced cardiomyocyte toxicity. Mechanistically, circ-ZNF609 knockdown alleviated DOX-induced cardiotoxicity through attenuating cardiomyocyte apoptosis, reducing reactive oxygen species production, ameliorating mitochondrial nonheme iron overload. circ-ZNF609 inhibition blocked the elevation of RNA N 6 -methyladenosine (RNA m 6 A) methylation level in DOX-treated mice hearts, whereas m 6 A demethylase fat mass and obesity associated (FTO) acted as the downstream factor of circ-ZNF609. Moreover, the stability of circ-ZNF609 was regulated by RNA m 6 A methylation alteration, and suppression of RNA m 6 A methylation by methyltransferase like 14 (METTL14) modulated the function of circ-ZNF609. These data suggest that circ-ZNF609 inhibition represents a potential therapy for DOX-induced cardiotoxicity.

本文使用的Yeasen产品

购物车
客服
转染试用